• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 12:23:51 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    SC 13G/A 1 dxcm13gadec20.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) DEXCOM INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 252131107 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 564,874 6. Shared Voting Power* 0 7. Sole Dispositive Power* 2,139,304 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,139,304 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 2.2% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: DEXCOM INC Item 1(b) Address of Issuer's Principal Executive Offices: 6340 SEQUENCE DRIVE, SAN DIEGO, CALIFORNIA 92121 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 252131107 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 16, 2021 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2020
    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    7/26/2024$161.00 → $80.00Outperform → Neutral
    Robert W. Baird
    7/26/2024$145.00 → $75.00Overweight → Neutral
    JP Morgan
    5/30/2024$130.00Neutral
    Redburn Atlantic
    More analyst ratings

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Dexcom with a new price target

      Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00

      6/16/25 7:46:45 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Dexcom with a new price target

      Goldman initiated coverage of Dexcom with a rating of Buy and set a new price target of $104.00

      5/30/25 8:41:14 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Dexcom with a new price target

      Mizuho initiated coverage of Dexcom with a rating of Outperform and set a new price target of $85.00

      4/10/25 12:40:59 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

      Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

      7/17/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

      MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies.  AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often devel

      7/15/25 8:45:00 AM ET
      $ABT
      $DXCM
      $IRTC
      $TNDM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

      7/1/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    SEC Filings

    See more
    • SEC Form SD filed by DexCom Inc.

      SD - DEXCOM INC (0001093557) (Filer)

      5/29/25 4:35:26 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • DexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - DEXCOM INC (0001093557) (Filer)

      5/13/25 8:31:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Amendment: DexCom Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:20:31 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Foletta Mark G sold $234,217 worth of shares (2,750 units at $85.17) (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      7/17/25 4:08:36 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Legal Officer Brown Michael Jon sold $43,015 worth of shares (500 units at $86.03), decreasing direct ownership by 0.53% to 94,602 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      7/17/25 4:03:07 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Gala Renee D was granted 1,161 shares, increasing direct ownership by 20% to 6,881 units (SEC Form 4)

      4/A - DEXCOM INC (0001093557) (Issuer)

      7/7/25 4:15:09 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

      Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

      7/17/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/13/24 5:02:33 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/23 11:16:37 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/22 3:43:37 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Financials

    Live finance-specific insights

    See more
    • Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

      7/1/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

      5/1/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start

      4/3/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care